secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001837607-25-000092
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma signs definitive exchange with Daewoong; $15M notes swapped for equity, new $1.5M note due 2030
--------------------------------------------------------------------------------

- Exchange eliminates >90% of AEON's outstanding debt; Daewoong receives ~23.1M shares, $1.5M new convertible note at 15.79% due Apr 2030.
- Daewoong gets cash-exercise warrant for 8M shares at $1.09392/share, representing up to $8M+ potential proceeds for AEON.
- Exchange remains subject to stockholder vote; closing expected after vote on Jan 21, 2026.
- Daewoong will nominate Seongsoo Park as Class III director at 2026 annual meeting; Park currently on board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/0001837607-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000092/aeon-20251215x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer